Form 4: Theravance Biopharma Director Alsup Laurie Smaldone Reports Share Transactions

Director Alsup Laurie Smaldone reports acquisition and disposal of Theravance Biopharma shares and options.

Summary

• On May 8, 2024, Alsup Laurie Smaldone, a director of Theravance Biopharma, reported transactions involving the company's securities.
• Smaldone acquired 10,537 ordinary shares at $0 and disposed of 64,331 ordinary shares.
• Following these transactions, Smaldone beneficially owns 64,331 ordinary shares.
• Smaldone also acquired 23,576 share options with an exercise price of $9.49, exercisable from May 8, 2024, and expiring on May 7, 2034.
• These options vest in monthly installments and fully vest on the next annual meeting date, contingent upon continuous service.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Future Outlook

The share options vest in monthly installments and fully vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, in their own company's stock. This allows the public to monitor insider activity, which can sometimes provide insights into management's view of the company's prospects.

Stakeholder Impact

• Shareholders can use this information to understand the trading activity of a key insider.
• Employees who also hold stock options may be interested in the vesting schedule and exercise price of the options granted to the director.

Key Dates